PBPK modeling predicts higher CBD exposure in many older adults
Predicting Cannabidiol Pharmacokinetics in Older Adults Via Physiologically Based Pharmacokinetic Modeling.
AI Summary
This in vitro and physiologically based pharmacokinetic (PBPK) modeling study examined how CBD is metabolized and whether age changes its expected exposure. The researchers evaluated the roles of cytochrome P450 (CYP) and UGT enzymes, as well as reversible and time-dependent enzyme inhibition. CBD showed time-dependent inhibition only of CYP1A2, and the abstract reports that this had a negligible effect on CBD metabolism. Adding the UGT activators alamethicin and magnesium chloride increased the apparent UGT contribution, potentially overestimating that pathway in laboratory tests.
After comparing model predictions with drug–drug interaction studies, the model best matched observed CBD exposure when metabolism was attributed 86% to CYP enzymes and 14% to UGT enzymes. Simulations generally predicted higher CBD exposure in older adults aged 65–98 years than in younger adults aged 18–64 years, although the difference depended on age and administration route. These findings may help with pharmacokinetic risk assessment, but this was a laboratory-and-modeling study rather than a direct clinical trial in older adults. As an abstract-based summary, it cannot establish how often higher modeled exposure occurs in real-world older people, whether it causes adverse effects, or what dose would be appropriate.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
A lab method measures 17 cannabinoids across five hemp product types
CBD showed limited adaptive-functioning differences versus placebo in boys…
NMR profiling finds THC predominates in Moroccan beldia extracts
Explore More Research
Stay informed about the latest cannabis science.